Capstone Holding Corp. · NASDAQ:CAPS
Capstone — Capstone Therapeutics — Corporate Update (November 2012)
15 slides from Capstone's corporate update, Nov 8, 2012
Slide 1: Capstone Therapeutics Operating Update
Capstone Therapeutics Operating Update November 8, 2012 AS CAPSTONE
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in this presentation or otherwise attributable to Capstone regarding our business that are not historical facts are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and
Slide 3: Cash Report
Cash Report YTD CAPS $ (662,000) $ (292,000) $ (445,000) —$ (1,399,000) Lipimetix - - $ (1,024,000) $ (1,024,000) Consolidated $ (662,000) $ (292,000) —$ (1,469,000) —$ (2,423,000) Cash Balance $13,116,000 $12,824,000 $ 11,355,000 $11,355,000 AS CAPSTONE 3
Slide 4: Qui Tam Lawsuit Update
Qui Tam Lawsuit Update > No lawsuit discovery initiated — duration of discovery process uncertain >» Lawsuit progress is stalled, awaiting DOJ settlement on fraud and kickback claims by other non-CAPS defendants >» Proposed DOJ/Orthofix settlement in December court review > Settlement/Trial: Timing
Slide 5: LipimetiX Development LLC (JV)
C LipimetiX Development LLC (JV) LLC Format CAPS contributed $6M for 60% (ownership) 2 tranche funding milestone to IND allowance $5M of CAPS contribution has preferential distribution right Lipimetix LLC (Lipi) contributed UAB license for current/future IP, for 40% (ownership) JV contracted Dennis
Slide 6: AEM-28 Rational Design at UAB
AEM-28 Rational Design at UAB — 299 aa down to 28 aa with full function Tings regen ASS S2 ny Apolipoprotein E LR AEM-28 Bx: Lipimerf ) CAPSTONE 8
Slide 7: Target Indications
Target Indications @ Homozygous Familial Hypercholesterolemia (HoFH) > Absence of LDL receptor function > Cannot clear LDL or control cholesterol levels > Orphan indication, potential for rapid development/ approval > Potential $200 million market @ Severe Refractory Hypercholesterolemia > Not respo
Slide 8: Target Indications -2
Target Indications -2 @ Acute Coronary Syndrome » 2,000,000 hospitalizations/year in US alone > 10-25% recurrence rate in first year after event >» Reduce atherosclerosis burden and mortality > Potential $11 Billion annual market > Will require an outcome study = S ipir CABSTONE , upimer@)
Slide 9: Fast-Track Development
Fast-Track Development due to unmet need, orphan drug status (foiled) ‘ive Cash 6 5 a4 o3 = 2 21 al) 3 € 3 oO 8 OQ BS 2 Q S 8 9) & 2 Q NS QD a + Phase 1 - Single ascending-dose study + (MTD, safety) in LDL>160 mg/dl ¥ Preliminary dose ranging ¥ Demonstrate LDL lowering + Phase 1b/2a - Multiple ascen
Slide 10: Homozygous FH Animal Evidence: AEM-28 Reduces LDL & VLDL
Homozygous FH Animal Evidence: AEM -28 Reduces LDL & VLDL >» Watanabe Heritable Hyperlipidemic (WHHL) Rabbits have same genetic defect as human FH patients > WHHL rabbits are refractory to statins, bile acid sequestrants, etc. » Single dose of AEM-28 reduces non-HDL cholesterol 45% at 18 hours al eV
Slide 11: ACS Animal Evidence: Direct Artery Wall Effects Reduce Atherosclerosis
ACS Animal Evidence: Direct Artery Wall Effects Reduce Atherosclerosis Reduction in Atherosclerosis far Exceeds Cholesterol Drop Control Animal Plasma Cholesterol = 1600 mg/dl 51% of aorta covered by fatty streaks AEM-28 Animal Plasma Cholesterol = 1100 mg/dl 8% of aorta covered by fatty streaks Lip
Slide 12: Summary — Apo E Mimetics
Summary — Apo E Mimetics @ Novel mimetics of key lipid/cholesterol metabolism protein > Utilizes alternate receptors on liver to clear atherogenic lipoproteins > Direct anti-inflammatory and lesion regression effects on artery > Believed to be only product in development with both effects @ Does not
Slide 13: LipimetiX Operating Update
LipimetiX Operating Update @ Joint Venture formation/Transaction completed on August 3, 2012 @ AEM-28 drug material manufactured/received @ Pre-IND meeting letter filed with FDA @ Orphan Drug application filed with FDA @ Preclinical Toxicity studies initiated @ IND vendors contracted Program on budg
Slide 14: Capstone Summary
Capstone Summary @ Three Programs: > Apo E Mimetic Peptide AEM-28 in LDL Reduction >» AZX100 in Pulmonary Fibrosis —- LRRI Results > AZX100 in Spinal (Epidural) Fibrosis — awaiting BNI results @ Continue Virtual Operation (1.5 Employees/ Consultants) to Preserve Cash @ Cash Resources Believed to be
Slide 15: Capstone Therapeutics contact details
C WD APSTON THERAPEUT OTCQB: CAPS www.capstonethx.com Capstone Therapeutics 1275 West Washington Street - Suite 101 Tempe, AZ 95281 (602) 286-5520 IE AS CAPSTONE 15
Capstone Therapeutics — Corporate Update (November 2012) on 6ix